Fate of Myeloma Drug's Comeback Now Rests in Hands of FDA Panel

(MedPage Today) — FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma remains murky given its checkered history in a briefing document released ahead of a meeting of the agency…

Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116511

Author :

Publish date : 2025-07-15 20:03:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel

Plant Extracts Relieve Hand Osteoarthritis

States Are Walking Back Medicaid Coverage for GLP-1s

Related Posts

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

NSCLC Survival Benefit Seen With EGFR-TKI + Chemo

Disabled doctors consider leaving NHS over shift inflexibility

Fracture Protection May Be Another Benefit of GLP-1 Receptor Agonists

Few Long-Term Bone Consequences After Teen Bariatric Surgery

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

NSCLC Survival Benefit Seen With EGFR-TKI + Chemo

Disabled doctors consider leaving NHS over shift inflexibility

Fracture Protection May Be Another Benefit of GLP-1 Receptor Agonists

Few Long-Term Bone Consequences After Teen Bariatric Surgery

‘I Don’t Know How Many Died’: What We Heard This Week

Osimertinib’s Benefits in NSCLC Can Extend Beyond First Line

Categories

Archives